JP2022514734A5 - - Google Patents
Info
- Publication number
- JP2022514734A5 JP2022514734A5 JP2021533155A JP2021533155A JP2022514734A5 JP 2022514734 A5 JP2022514734 A5 JP 2022514734A5 JP 2021533155 A JP2021533155 A JP 2021533155A JP 2021533155 A JP2021533155 A JP 2021533155A JP 2022514734 A5 JP2022514734 A5 JP 2022514734A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr
- pharmaceutical composition
- antibody
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025086417A JP2025128164A (ja) | 2018-12-11 | 2025-05-23 | 抗ｔｒｅｍ２抗体の使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2018/065026 | 2018-12-11 | ||
| PCT/US2018/065026 WO2019118513A1 (en) | 2017-12-12 | 2018-12-11 | Anti-trem2 antibodies and related methods |
| US201962889990P | 2019-08-21 | 2019-08-21 | |
| US62/889,990 | 2019-08-21 | ||
| PCT/US2019/065743 WO2020123664A1 (en) | 2018-12-11 | 2019-12-11 | Methods of using anti-trem2 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025086417A Division JP2025128164A (ja) | 2018-12-11 | 2025-05-23 | 抗ｔｒｅｍ２抗体の使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514734A JP2022514734A (ja) | 2022-02-15 |
| JP2022514734A5 true JP2022514734A5 (enExample) | 2022-12-15 |
| JP7688579B2 JP7688579B2 (ja) | 2025-06-04 |
Family
ID=71076653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533155A Active JP7688579B2 (ja) | 2018-12-11 | 2019-12-11 | 抗ｔｒｅｍ２抗体の使用方法 |
| JP2025086417A Pending JP2025128164A (ja) | 2018-12-11 | 2025-05-23 | 抗ｔｒｅｍ２抗体の使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025086417A Pending JP2025128164A (ja) | 2018-12-11 | 2025-05-23 | 抗ｔｒｅｍ２抗体の使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12668629B2 (enExample) |
| EP (1) | EP3893931A4 (enExample) |
| JP (2) | JP7688579B2 (enExample) |
| KR (1) | KR20210104079A (enExample) |
| CN (1) | CN113194994B (enExample) |
| AU (1) | AU2019397479A1 (enExample) |
| CA (1) | CA3120875A1 (enExample) |
| WO (1) | WO2020123664A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| CA3120875A1 (en) | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| IL285416A (en) * | 2021-08-05 | 2023-03-01 | Yeda Res & Dev | Antibodies for cancer treatment |
| CN113929785B (zh) * | 2021-09-10 | 2023-05-23 | 钦元再生医学(珠海)有限公司 | 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用 |
| WO2024250809A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都优洛生物科技有限公司 | 抗trem2全人源抗体或其抗原结合片段及其应用 |
| WO2025046298A2 (en) * | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| CN119735683B (zh) * | 2023-12-21 | 2025-10-31 | 华润生物医药有限公司 | 抗trem2抗体及其用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7294331B2 (en) | 1994-03-07 | 2007-11-13 | Immunex Corporation | Methods of using flt3-ligand in hematopoietic cell transplantation |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| ES2272448T3 (es) | 2000-03-15 | 2007-05-01 | Genexine Co., Ltd. | Genes de la subunidad il-12p40 mutados para mejorar la actividad de il-12 y uso de los mismos en un coadyuvante de vacuna genetica. |
| US7442777B2 (en) | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US20070213660A1 (en) | 2004-10-29 | 2007-09-13 | Mark Richards | Fibrin sealant delivery device including pressure monitoring, and method and kits thereof |
| EP1882392A4 (en) | 2005-05-10 | 2009-07-01 | Monsanto Technology Llc | GENES AND THEIR USES FOR PLANT IMPROVEMENTS |
| ES2547463T3 (es) | 2005-06-17 | 2015-10-06 | Merck Sharp & Dohme Corp. | Moléculas de unión a ILT3 y usos de las mismas |
| WO2007089945A2 (en) | 2006-02-02 | 2007-08-09 | The Trustees Of Columbia University In The City Of New York | Treating diseases by targeting silt3 |
| WO2008094176A2 (en) | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| AU2010339359A1 (en) | 2009-12-29 | 2012-07-26 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD27 antibody |
| CA2793657A1 (en) | 2010-03-18 | 2011-09-22 | Colorado State University Research Foundation | Myeloid derived suppressor cell inhibiting agents |
| US20110262348A1 (en) | 2010-03-29 | 2011-10-27 | Vrije Universiteit Brussel | Selective targeting of intratumoral cells |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| WO2012149416A2 (en) | 2011-04-28 | 2012-11-01 | University Of Southern California | Human myeloid derived suppressor cell cancer markers |
| US9696312B2 (en) | 2011-09-02 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand |
| ES2715279T3 (es) | 2012-05-24 | 2019-06-03 | Vib Vzw | Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores |
| US20150191543A1 (en) | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| TW201726746A (zh) | 2012-11-07 | 2017-08-01 | 輝瑞股份有限公司 | 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體 |
| WO2014074942A1 (en) | 2012-11-08 | 2014-05-15 | Illumina, Inc. | Risk variants of alzheimer's disease |
| EP2964648B1 (en) | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| WO2015035365A1 (en) | 2013-09-09 | 2015-03-12 | The Nohns Hopkins University | Targeting the m2-tumor associated macrophage for cancer therapy |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| EA201790342A1 (ru) * | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| US20170334977A1 (en) | 2014-10-20 | 2017-11-23 | The Brigham And Women's Hospital, Inc. | Targeting Apolipoprotein E (APOE) in Neurologic Disease |
| EP3789039A1 (en) | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| JP7725185B2 (ja) * | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| SG11201808693WA (en) * | 2016-04-27 | 2018-11-29 | Pfizer | Anti-il-33 antibodies, compositions, methods and uses thereof |
| JP2019531332A (ja) | 2016-07-22 | 2019-10-31 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー．ファウ．（デーツェットエンエー） | Ｔｒｅｍ２切断モジュレーター及びその使用 |
| US10167796B2 (en) | 2017-05-17 | 2019-01-01 | GM Global Technology Operations LLC | Gasoline particulate filter regeneration strategy |
| BR112020001060A2 (pt) | 2017-07-27 | 2020-07-14 | Novartis Ag | variantes de trem2 resistentes a shedase |
| HUE062436T2 (hu) | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| MX2020006213A (es) * | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| CA3120875A1 (en) | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
-
2019
- 2019-12-11 CA CA3120875A patent/CA3120875A1/en active Pending
- 2019-12-11 WO PCT/US2019/065743 patent/WO2020123664A1/en not_active Ceased
- 2019-12-11 KR KR1020217021577A patent/KR20210104079A/ko not_active Ceased
- 2019-12-11 CN CN201980081883.4A patent/CN113194994B/zh active Active
- 2019-12-11 EP EP19895894.4A patent/EP3893931A4/en not_active Withdrawn
- 2019-12-11 JP JP2021533155A patent/JP7688579B2/ja active Active
- 2019-12-11 AU AU2019397479A patent/AU2019397479A1/en active Pending
-
2021
- 2021-06-10 US US17/344,839 patent/US12668629B2/en active Active
-
2025
- 2025-05-23 JP JP2025086417A patent/JP2025128164A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506244A5 (enExample) | ||
| JP7438939B2 (ja) | Ｃｄ１３７を標的とする抗体とその利用方法 | |
| KR102522693B1 (ko) | 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체 | |
| JP2021531005A5 (enExample) | ||
| EP3470426A1 (en) | Multispecific antibody | |
| AU2018348429A1 (en) | Multispecific antibody | |
| ME02093B (me) | Antitijela za humani receptor programirane smrti pd-1 | |
| JP2021514973A5 (enExample) | ||
| CN108136001A (zh) | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 | |
| JP2022533538A5 (enExample) | ||
| CN111808190B (zh) | 结合pd-1的抗体 | |
| EP3356401A1 (en) | Binding molecules with modified j-chain | |
| TW202222835A (zh) | 抗ＳＩＲＰα抗體及其用途 | |
| JP2023549555A5 (enExample) | ||
| AU2017379382A1 (en) | Anti-CD3 Antibody and Molecules Comprising the Antibody | |
| AU2017358359B2 (en) | Antibody binding specifically to CD66c and use thereof | |
| EP4408478A1 (en) | B7-h4 antibody-drug conjugates for the treatment of cancer | |
| KR20180118220A (ko) | Gitr 항체, 방법, 및 용도 | |
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| CN115210261A (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| KR20200063147A (ko) | Pdl1 표적화 항체 및 이의 사용 방법 | |
| JP2025511288A (ja) | 抗ｐｖｒｉｇ抗体、その医薬組成物及びその使用 | |
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP2022523145A5 (enExample) | ||
| CN119095873A (zh) | 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合 |